Positive new data on Roche’s Lunsumio and Polivy combo

Swiss pharma giant Roche (ROG: SIX) has released encouraging results from the Phase III SUNMO study showing Lunsumio (mosunetuzumab) administered subcutaneously in combination with Polivy (polatuzumab vedotin), delivered a seismic update in aggressive lymphoma therapy.

The study demonstrated a clinically-meaningful and statistically-significant improvement in its primary endpoints of progression-free survival (PFS) and objective response rate (ORR) compared to MabThera/Rituxan (rituximab), gemcitabine and oxaliplatin (R-GemOx), in people with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) who are not eligible for transplant. Primary analysis data were featured at the 18th International Conference on Malignant Lymphoma as a late-breaking oral presentation.

Roche noted that the results from the SUNMO study will be submitted to global health authorities, including the US Food and Drug Administration (FDA). The National Comprehensive Cancer Network (NCCN) has recently added Lunsumio and Polivy to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) as a category 2A recommendation for the treatment of people with second-line (2L) diffuse large B-cell lymphoma (DLBCL) who are not intended to proceed to transplant.